Annotation Detail
Information
- Associated Genes
- PIK3CA
- Associated Variants
-
PIK3CA AMPLIFICATION
(
ENST00000263967.4 )
PIK3CA AMPLIFICATION ( ENST00000263967.4, ENST00000497599.5 ) - Associated Disease
- head and neck squamous cell carcinoma
- Source Database
- CIViC Evidence
- Description
- The HNSCC cell line LB771 with PIK3CA amplification was shown to have low antiproliferative IC50 for the p110beta-sparing PI3K inhibitor taselisib. Under increasing taselisib concentrations, reduction in phospho-Akt pro-survival signal was apparent, along with increased levels of pro-apoptotic marker cleaved PARP. A general tendency for taselisib sensitivity to PI3K activation (mutation/amplification) was also seen in a panel of 26 HNSCC cell lines
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1464
- Gene URL
- https://civic.genome.wustl.edu/links/genes/37
- Variant URL
- https://civic.genome.wustl.edu/links/variants/212
- Rating
- 1
- Evidence Type
- Predictive
- Disease
- Head And Neck Squamous Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Taselisib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26589432
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Taselisib | Sensitivity | true |